Mizuho Markets Americas LLC Has $3.01 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Mizuho Markets Americas LLC trimmed its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 1.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,068 shares of the medical device company’s stock after selling 1,188 shares during the period. Mizuho Markets Americas LLC’s holdings in Tandem Diabetes Care were worth $3,014,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Assetmark Inc. acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at $29,000. ORG Wealth Partners LLC acquired a new stake in shares of Tandem Diabetes Care in the third quarter worth about $30,000. ORG Partners LLC bought a new stake in shares of Tandem Diabetes Care during the 2nd quarter worth about $31,000. Headlands Technologies LLC acquired a new position in shares of Tandem Diabetes Care during the 1st quarter valued at about $35,000. Finally, Waldron Private Wealth LLC bought a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $50,000.

Tandem Diabetes Care Trading Down 4.4 %

Shares of TNDM opened at $27.34 on Friday. Tandem Diabetes Care, Inc. has a 12 month low of $17.33 and a 12 month high of $53.69. The company has a 50-day moving average price of $37.46 and a two-hundred day moving average price of $41.64. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. During the same quarter in the previous year, the firm earned ($0.38) EPS. Tandem Diabetes Care’s quarterly revenue was up 31.4% on a year-over-year basis. On average, research analysts predict that Tandem Diabetes Care, Inc. will post -1.73 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TNDM shares. Morgan Stanley reissued an “equal weight” rating and issued a $45.00 price target on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. Canaccord Genuity Group started coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They set a “buy” rating and a $57.00 price target for the company. Wells Fargo & Company lifted their price objective on Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. The Goldman Sachs Group started coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 target price for the company. Finally, Canaccord Genuity Group dropped their price target on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.25.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.